By: Allen Wilbanks
Date: October 03, 2023
Julie Vose, MD, a respected expert in the field of lymphoma, began her presentation by acknowledging the challenging nature of mantle cell lymphoma and introduced herself with the following quote: “Thank you very much. So it’s my pleasure to talk about mantle cell lymphoma, another challenging lymphoma. These are my disclosures.”
She went on to provide valuable insights into mantle cell lymphoma, emphasizing its prevalence, gender distribution, and the often advanced stage at which patients are diagnosed. Julie stated, “Mantle cell lymphoma, not the most common lymphoma, about sixty nine percent, and patients are typically a little bit older, but it’s much more common in men than in women. And almost all patients have advanced stage disease at the time of diagnosis, particularly in unusual spots.”
Julie described a typical patient case, a sixty-one-year-old female, to illustrate the disease’s characteristics and challenges. She discussed the patient’s clinical presentation, treatment history, and response to therapy.
The presentation delved into the different subtypes of mantle cell lymphoma and how they can behave differently, emphasizing the importance of accurate diagnosis. Julie also discussed risk factors and the MIPI classification, which helps assess prognosis.
The evolving treatment landscape for mantle cell lymphoma was a key focus of Julie’s presentation. She discussed the Triangle study, which introduced significant changes to treatment recommendations, especially regarding the use of BTK inhibitors and autologous transplant. She highlighted the impact of the study’s results on NCCN guidelines.
Julie touched on novel therapeutic approaches, including BTK inhibitors, CAR T-cell therapy, and bispecific antibodies. She shared data on their effectiveness and discussed ongoing studies in the field.
In conclusion, Julie outlined the remaining questions and challenges in mantle cell lymphoma management. She addressed topics such as upfront therapy, the role of auto transplant, maintenance therapy, and the impact of COVID-19 on treatment decisions.
Overall, Julie Vose, MS, provided a comprehensive and informative presentation on mantle cell lymphoma, offering valuable insights into its diagnosis and management.